Company intelligence / Profile preview

ViruDefense

Burlington, Massachusetts, United States

Ownership: Private
Development stage: Other

Overview

ViruDefense developed the VDI-100 mask, which combines N95 respirator filtration capabilities with surgical mask fluid resistance. The mask was one of only 18 products on the CDC's Certified Equipment List for N95 masks during the COVID-19 pandemic. Prior to acquisition, ViruDefense had delivered over 10 million N95 masks to healthcare workers with manufacturing capacity exceeding one million units per week.

Therapeutic areas: PulmonologyInfectious Diseases
Modalities: Device
Industry: Consumable Medical Devices

Partnerships

TEAM Technologies (acquirer)

Beyond the preview

Go deeper on ViruDefense.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ViruDefense.

Explore the full profile